8-K: Soleno Therapeutics Achieves Profitability, Strong VYKAT XR Sales

Soleno Therapeutics reported a profitable third quarter 2025 with $66.0 million in VYKAT XR revenue and a positive net income of $26.0 million, driven by a successful product launch.

Summary

• Generated $66.0 million in net revenue from VYKAT XR sales for the three months ended September 30, 2025, a significant increase from $0 in the prior year period and more than 100% sequentially from $32.7 million in Q2 2025.
• Achieved profitability with a net income of $26.0 million, or $0.47 per diluted share, for Q3 2025, compared to a net loss of $(76.6) million, or $(1.83) per diluted share, in Q3 2024.
• Reported $43.5 million in cash generated from operating activities during Q3 2025.
• Ended the quarter with $556.1 million in cash, cash equivalents, and marketable securities, which includes $230 million in gross proceeds from an underwritten common stock offering in July.
• Since VYKAT XR approval on March 26, 2025, through September 30, 2025, 1,043 patient start forms have been received (397 in Q3), 494 unique prescribers have been identified (199 in Q3), and 764 patients are actively on drug.
• VYKAT XR covers over 132 million lives.
• Appointed Mark W. Hahn to the Board of Directors and as a member of the Audit Committee.

Sentiment

Score: 9

Explanation: The company reported a significant financial turnaround, achieving profitability and substantial revenue growth from its newly launched, FDA-approved product, VYKAT XR. Strong patient and prescriber uptake, coupled with a successful capital raise, indicate robust commercial execution and a strong financial position. The product addresses a critical unmet need in a rare disease, positioning the company for continued growth.

Positives

• Achieved significant revenue of $66.0 million from VYKAT XR sales in Q3 2025, demonstrating strong commercial traction for its newly approved product.
• Returned to profitability with a net income of $26.0 million in Q3 2025, a substantial turnaround from a net loss of $(76.6) million in the same period last year.
• Generated $43.5 million in cash from operating activities, indicating healthy operational cash flow.
• Maintained a robust cash position with $556.1 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
• Successfully raised $230 million in gross proceeds through an underwritten offering of common stock, strengthening the balance sheet.
• Demonstrated strong patient and prescriber uptake for VYKAT XR, with 764 active patients and 494 unique prescribers since launch.
• VYKAT XR is the first and only FDA-approved therapy for hyperphagia in patients 4 years and older with Prader-Willi syndrome, addressing a significant unmet medical need.

Negatives

• Selling, general and administrative expenses are expected to continue to increase following the commercialization of VYKAT XR.
• The fair value of the contingent liability for Essentialis purchase price increased by $0.6 million to $19.5 million as of September 30, 2025, primarily due to increasing sales of VYKAT XR, indicating future cash outflows.

Risks

• Hyperglycemia, including diabetic ketoacidosis, has been reported with VYKAT XR use, requiring monitoring of fasting plasma glucose and HbA1c.
• Risk of fluid overload and edema, including severe reactions, has been reported, requiring monitoring for signs or symptoms of edema or fluid overload.
• VYKAT XR has not been studied in patients with compromised cardiac reserve and should be used with caution in these patients.
• The company's forward-looking statements are subject to risks, uncertainties, and assumptions, and actual results could differ materially from projections.

Future Outlook

Selling, general and administrative expenses are expected to continue to increase following the commercialization of VYKAT XR. The cadence of research and development expenditures will fluctuate depending upon the state of clinical programs, timing of manufacturing, and other projects supporting regulatory filings and commercial launch activities. VYKAT XR is believed to have the potential to become a foundational therapy for patients with hyperphagia associated with Prader-Willi syndrome.

Management Comments

• Strong third quarter results reflect growing awareness of VYKAT XR's compelling efficacy and safety profile within the PWS community.
• As the first and only FDA-approved therapy for hyperphagia in PWS patients 4 years and older, VYKAT XR offers a new option for this fragile and complex patient population.
• The favorable efficacy and safety profile of VYKAT XR from the clinical program includes over 100 patients on therapy for greater than one year, with many on continuous therapy for over six years.
• We believe VYKAT XR has the potential to become a foundational therapy for patients with hyperphagia associated with PWS, and we are working tirelessly to make it as broadly accessible as possible.

Industry Context

Soleno Therapeutics' VYKAT XR is positioned as the first and only FDA-approved therapy specifically for hyperphagia in Prader-Willi syndrome (PWS) patients aged 4 years and older. This establishes Soleno as a leader in addressing a significant unmet medical need within the rare disease space, potentially setting a new standard of care for PWS patients suffering from this life-threatening condition. The successful launch and rapid patient uptake suggest strong market acceptance for a targeted therapy in a rare disease with limited treatment options.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to significant revenue growth, return to profitability, strong cash position, and successful capital raise, likely leading to increased shareholder value.
• Patients with Prader-Willi Syndrome: Highly positive impact as VYKAT XR is the first and only FDA-approved therapy for hyperphagia, offering a new and effective treatment option.
• Prescribers: Positive impact as a new, effective, and FDA-approved treatment option for a challenging rare disease becomes available.
• Employees: Increased personnel and associated costs due to hiring additional employees for commercial launch and increased business activities, indicating growth and job opportunities.

Next Steps

• Continue commercialization efforts to make VYKAT XR broadly accessible to patients with Prader-Willi syndrome.
• Host an investor conference call and webcast on November 4, 2025, to discuss financial and operating results and provide further updates on the VYKAT XR launch.

Key Dates

Recommendation

Soleno Therapeutics has demonstrated exceptional performance in Q3 2025, achieving profitability and substantial revenue growth from its newly launched, FDA-approved drug, VYKAT XR. The product addresses a significant unmet medical need in Prader-Willi syndrome, positioning the company as a market leader. Strong patient and prescriber uptake, coupled with a robust cash position bolstered by a recent $230 million capital raise, provide a solid foundation for continued commercial success and future growth. The financial turnaround and successful product launch indicate strong operational execution and significant upside potential for investors.

Keywords

Soleno Therapeutics, SLNO, VYKAT XR, Prader-Willi syndrome, hyperphagia, rare disease, biopharmaceutical, Q3 2025 financial results, FDA approval, drug launch, profitability, cash flow, capital raise